Effect of thalidomide on the proliferation of hepatoma cells assessed by osteopontin levels in nude mice

Lin,Fan; Cao,Jie; Huang,Zhiming; Pei,Zhenghao; Gu,Weili; Fan,Shaofeng; Li,Kunping; Weng,Jiefeng

doi:10.3892/etm.2013.1010

Effect of thalidomide on the proliferation of hepatoma cells assessed by osteopontin levels in nude mice

Authors:
- Fan Lin
- Jie Cao
- Zhiming Huang
- Zhenghao Pei
- Weili Gu
- Shaofeng Fan
- Kunping Li
- Jiefeng Weng
View Affiliations

Affiliations: Department of General Surgery, The First People's Hospital Affiliated to Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China, Department of General Surgery, The First People's Hospital Affiliated to Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China, Department of General Surgery, Guangdong General Hospital, Guangzhou, Guangdong 510030, P.R. China
Published online on: March 15, 2013 https://doi.org/10.3892/etm.2013.1010
Pages: 1403-1407

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the inhibitory effects of thalidomide in the hepatocellular carcinoma nude mouse model in order to provide new insights into a comprehensive clinical intervention for hepatocellular carcinoma. MHCC97 cells were routinely cultured, passaged and adjusted to a single cell suspension with a concentration of 2x107/ml. Six‑week‑old, BALB/C male nude mice were anesthetized and fixed in the prone position, then a subcapsular injection of the single cell suspension was administered into the spleen and their abdomens were closed. A laparotomy and left hepatic lobectomy was performed 14 days later and the abdomens were closed once again. Subsequent to the establishment of the hepatocellular carcinoma model, the nude mice were randomly divided into three groups, each consisting of 12 mice. The early intervention group were immediately provided with the post‑operative thalidomide intervention, the late intervention group were provided with the post‑operative thalidomide intervention one week subsequent to the surgery, and the negative control group were provided with a placebo intervention (0.9% physiological saline). Each intervention was continuously administered once per day for one week. The osteopontin (OPN) content of the liver tumors was detected using immunohistochemistry. The data were analyzed using an analysis of variance (ANOVA) test. There were significant differences in the OPN levels of the tumors among the early intervention, late intervention and negative control groups. Thalidomide may inhibit the generation of OPN and thereby inhibit the infiltration and metastasis of tumors; the immediate use of thalidomide following hepatectomy in the present study may block the invasion and metasis for liver cancer more effectively.

View Figures

View References

1.	Tang ZY, Ye SL, Liu YK, et al: A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 130:187–196. 2004.
2.	Qin LX and Tang ZY: Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 130:497–513. 2004.PubMed/NCBI
3.	D’Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:4082–4085. 1994.
4.	Shortt J, Hsu AK and Johnstone RW: Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene. Jan 14–2013.[Epub ahead of print].
5.	Chen YY, Yen HH, Chou KC and Wu SS: Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis. World J Gastroenterol. 18:466–471. 2012. View Article : Google Scholar : PubMed/NCBI
6.	Ang SF, Tan SH, Toh HC, Poon DY, Ong SY, Foo KF and Choo SP: Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. Am J Clin Oncol. 35:222–227. 2012. View Article : Google Scholar : PubMed/NCBI
7.	Garrison LJ Jr, Wang ST, Huang H, et al: The cost-effectiveness of initial treatment of multiple myeloma in the u.s. With bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist. 18:27–36. 2013.
8.	Ue T, Yokozaki H, Kitadai Y, et al: Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 79:127–132. 1998. View Article : Google Scholar : PubMed/NCBI
9.	Wallach RC: Osteopontin as a biomarker for ovarian cancer. JAMA. 287:3209–3210. 2002.
10.	Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Wai PY and Kuo PC: The role of Osteopontin in tumor metastasis. J Surg Res. 121:228–241. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Teramoto H, Castellone MD, Malek RL, et al: Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene. 24:489–501. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Gao C, Guo H, Downey L, Marroquin C, Wei J and Kuo PC: Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis. 24:1871–1878. 2003. View Article : Google Scholar : PubMed/NCBI
14.	Guo H, Marroquin CE, Wai PY and Kuo PC: Nitric oxide-dependent osteopontin expression induces metastatic behavior in HepG2 cells. Dig Dis Sci. 50:1288–1298. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Zhang GX, Zhao ZQ, Wang HD and Hao B: Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway. World J Gastroenterol. 10:205–208. 2004.PubMed/NCBI
16.	Reginato MJ, Mills KR, Paulus JK, et al: Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol. 5:733–740. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Nishimichi N, Hayashita-Kinoh H, Chen C, et al: Osteopontin undergoes polymerization in vivo and gains chemotactic activity for neutrophils mediated by integrin alpha9beta1. J Biol Chem. 286:11170–11178. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Budhu AS, Zipser B, Forgues M, et al: The molecular signature of metastases of human hepatocellular carcinoma. Oncology. 69(Suppl 1): 23–27. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Pan HW, Ou YH, Peng SY, et al: Overexpression of osteopontin is associated with intrahepatic matastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 98:119–127. 2003. View Article : Google Scholar
20.	Lin F, Li Y, Cao J, et al: Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells. Mol Biol Rep. 38:5205–5210. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Yamazaki H, Suemizu H, Igaya S, et al: In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice. Chem Res Toxicol. 24:287–289. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Majumdar S, Lamothe B and Aggarwal BB: Thalidomide suppresses NF-kappa B activation induced by TNF and H₂O₂, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol. 168:2644–2651. 2002. View Article : Google Scholar : PubMed/NCBI
23.	Eichholz A, Merchant S and Gaya AM: Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther. 3:69–82. 2010.PubMed/NCBI
24.	Stewart EE, Sun H, Chen X, Schafer PH, Chen Y, Garcia BM and Lee TY: Effect of an angiogenesis inhibitor on hepatic tumor perfusion and the implications for adjuvant cytotoxic therapy. Radiology. 264:68–77. 2012. View Article : Google Scholar : PubMed/NCBI
25.	Kappler M, Taubert H, Holzhausen HJ, et al: Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parmeters. Strahlenther Onkol. 184:393–399. 2008. View Article : Google Scholar : PubMed/NCBI